NDC 73380-4700

LUMOXITI

Moxetumomab Pasudotox

LUMOXITI is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Innate Pharma, Inc.. The primary component is Moxetumomab Pasudotox.

Product ID73380-4700_50a54d82-8f62-4e80-a35f-cd51a48bb0e5
NDC73380-4700
Product TypeHuman Prescription Drug
Proprietary NameLUMOXITI
Generic NameMoxetumomab Pasudotox
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2020-05-15
Marketing CategoryBLA / BLA
Application NumberBLA761104
Labeler NameInnate Pharma, Inc.
Substance NameMOXETUMOMAB PASUDOTOX
Active Ingredient Strength1 mg/mL
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 73380-4700-1

1 VIAL in 1 CARTON (73380-4700-1) > 1 mL in 1 VIAL
Marketing Start Date2020-05-15
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 73380-4700-1 [73380470001]

LUMOXITI INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Marketing CategoryBLA
Application NumberBLA761104
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2020-05-15

Drug Details

NDC Crossover Matching brand name "LUMOXITI" or generic name "Moxetumomab Pasudotox"

NDCBrand NameGeneric Name
0310-4700LUMOXITImoxetumomab pasudotox
73380-4700LUMOXITIMOXETUMOMAB PASUDOTOX

Trademark Results [LUMOXITI]

Mark Image

Registration | Serial
Company
Trademark
Application Date
LUMOXITI
LUMOXITI
87778486 5610169 Live/Registered
INNATE PHARMA S.A.
2018-01-31

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.